|
1
|
Ronco P and Debiec H: Pathophysiological
advances in membranous nephropathy: Time for a shift in patient's
care. Lancet. 385:1983–1992. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Cattran DC and Brenchley PE: Membranous
nephropathy: Integrating basic science into improved clinical
management. Kidney Int. 91:566–574. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Couser WG: Primary membranous nephropathy.
Clin J Am Soc Nephrol. 12:983–997. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Beck LH Jr, Bonegio RG, Lambeau G, Beck
DM, Powell DW, Cummins TD, Klein JB and Salant DJ: M-type
phospholipase A2 receptor as target antigen in idiopathic
membranous nephropathy. N Engl J Med. 361:11–21. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tomas NM, Beck LH Jr, Meyer-Schwesinger C,
Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U,
Dabert-Gay AS, et al: Thrombospondin type-1 domain-containing 7A in
idiopathic membranous nephropathy. N Engl J Med. 371:2277–2287.
2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ponticelli C, Zucchelli P, Passerini P,
Cesana B, Locatelli F, Pasquali S, Sasdelli M, Redaelli B, Grassi
C, Pozzi C, et al: A 10-year follow-up of a randomized study with
methylprednisolone and chlorambucil in membranous nephropathy.
Kidney Int. 48:1600–1604. 1995.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hladunewich MA, Troyanov S, Calafati J and
Cattran DC: Metropolitan Toronto Glomerulonephritis Registry. The
natural history of the non-nephrotic membranous nephropathy
patient. Clin J Am Soc Nephrol. 4:1417–1422. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zuo K, Wu Y, Li SJ, Xu F, Zeng CH and Liu
ZH: Long-term outcome and prognostic factors of idiopathic
membranous nephropathy in the Chinese population. Clin Nephrol.
79:445–453. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
van den Brand JA, Hofstra JM and Wetzels
JF: Low-molecular-weight proteins as prognostic markers in
idiopathic membranous nephropathy. Clin J Am Soc Nephrol.
6:2846–2853. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ruggenenti P, Fervenza FC and Remuzzi G:
Treatment of membranous nephropathy: Time for a paradigm shift. Nat
Rev Nephrol. 13:563–579. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Segal PE and Choi MJ: Recent advances and
prognosis in idiopathic membranous nephropathy. Adv Chronic Kidney
Dis. 19:114–119. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Waldman M and Austin HA III: Controversies
in the treatment of idiopathic membranous nephropathy. Nat Rev
Nephrol. 5:469–479. 2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
van den Brand JA, Hofstra JM and Wetzels
JF: Prognostic value of risk score and urinary markers in
idiopathic membranous nephropathy. Clin J Am Soc Nephrol.
7:1242–1248. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cattran DC, Pei Y, Greenwood CM,
Ponticelli C, Passerini P and Honkanen E: Validation of a
predictive model of idiopathic membranous nephropathy: Its clinical
and research implications. Kidney Int. 51:901–907. 1997.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pei Y, Cattran D and Greenwood C:
Predicting chronic renal insufficiency in idiopathic membranous
glomerulonephritis. Kidney Int. 42:960–966. 1992.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Shiiki H, Saito T, Nishitani Y, Mitarai T,
Yorioka N, Yoshimura A, Yokoyama H, Nishi S, Tomino Y, Kurokawa K,
et al: Prognosis and risk factors for idiopathic membranous
nephropathy with nephrotic syndrome in Japan. Kidney Int.
65:1400–1407. 2004.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Schieppati A, Mosconi L, Perna A, Mecca G,
Bertani T, Garattini S and Remuzzi G: Prognosis of untreated
patients with idiopathic membranous nephropathy. N Engl J Med.
329:85–89. 1993.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chembo CL, Marshall MR, Williams LC,
Walker RJ, Lynn KL, Irvine J and Pilmore HL: Long-term outcomes for
primary glomerulonephritis: New Zealand glomerulonephritis study.
Nephrology (Carlton). 20:899–907. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Dähnrich C, Komorowski L, Probst C,
Seitz-Polski B, Esnault V, Wetzels JF, Hofstra JM, Hoxha E, Stahl
RA, Lambeau G, et al: Development of a standardized ELISA for the
determination of autoantibodies against human M-type phospholipase
A2 receptor in primary membranous nephropathy. Clin Chim Acta.
421:213–218. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Foundation NK: KDIGO clinical practice
guideline for glomerulonephritis. Kidney Int Suppl. 2(142)2012.
|
|
21
|
Matsushita K, Selvin E, Bash LD, Astor BC
and Coresh J: Risk implications of the new CKD epidemiology
collaboration (CKD-EPI) equation compared with the MDRD study
equation for estimated GFR: The atherosclerosis risk in communities
(ARIC) study. Am J Kidney Dis. 55:648–659. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Brien EO, Atkins N and Malley KO: Defining
normal ambulatory blood pressure. Am J Hypertens. 6:201S–206S.
1993.PubMed/NCBI
|
|
23
|
Fogo AB, Lusco MA, Najafian B and Alpers
CE: AJKD atlas of renal pathology: Membranous nephropathy. Am J
Kidney Dis. 66:e15–e17. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ehrenreich T, Porush JG, Churg J,
Garfinkel L, Glabman S, Goldstein MH, Grishman E and Yunis SL:
Treatment of idiopathic membranous nephropathy. N Engl J Med.
295:741–746. 1976.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Working Group of the International IgA
Nephropathy Network and the Renal Pathology Society. Cattran DC,
Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE,
Amore A, Barratt J, et al: The Oxford classification of IgA
nephropathy: rationale, clinicopathological correlations, and
classification. Kidney Int. 76:534–545. 2009.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Harrell FE Jr: Rms: Regression modeling
strategies. R package version 5.1-0, Journal, 2017.
|
|
27
|
Therneau TM and Grambsch PM: Modeling
survival data: Extending the Cox model. Springer Science &
Business Media, 2013.
|
|
28
|
Akaike H: Information theory and an
extension of the maximum likelihood principle. In: Selected papers
of hirotugu akaike. New York, Springer, pp199-213, 1998.
|
|
29
|
Grambsch PM and Therneau TM: Proportional
hazards tests and diagnostics based on weighted residuals.
Biometrika. 81:515–526. 1994.
|
|
30
|
Harrell FE Jr: Dupont wcfC and others. m:
Hmisc: Harrell Miscellaneous. R package version 4.0-3, Journal,
2017.
|
|
31
|
Team RC: R: A language and environment for
statistical computing. Journal, 2017.
|
|
32
|
Fervenza FC, Sethi S and Specks U:
Idiopathic membranous nephropathy: Diagnosis and treatment. Clin J
Am Soc Nephrol. 3:905–919. 2008.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Polanco N, Gutiérrez E, Covarsí A, Ariza
F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C,
Pons S, et al: Spontaneous remission of nephrotic syndrome in
idiopathic membranous nephropathy. J Am Soc Nephrol. 21:697–704.
2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhang XD, Cui Z, Zhang MF, Wang J, Zhang
YM, Qu Z, Wang X, Huang J, Wang F, Meng LQ, et al: Clinical
implications of pathological features of primary membranous
nephropathy. BMC Nephrol. 19(215)2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chen Y, Tang L, Feng Z, Cao X, Sun X, Liu
M, Liu S, Zhang X, Li P, Wei R, et al: Pathological predictors of
renal outcomes in nephrotic idiopathic membranous nephropathy with
decreased renal function. J Nephrol. 27:307–316. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Horvatic I, Ljubanovic DG, Bulimbasic S,
Knotek M, Prkacin I, Tisljar M and Galesic K: Prognostic
significance of glomerular and tubulointerstitial morphometry in
idiopathic membranous nephropathy. Pathol Res Pract. 208:662–667.
2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Reichert LJ, Koene RA and Wetzels JF:
Prognostic factors in idiopathic membranous nephropathy. Am J
Kidney Dis. 31:1–11. 1998.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Mwasongwe SE, Fülöp T, Katz R, Musani SK,
Sims M, Correa A, Flessner MF and Young BA: Relation of uric acid
level to rapid kidney function decline and development of kidney
disease: The Jackson heart study. J Clin Hypertens (Greenwich).
20:775–783. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Iseki K: Significance of hyperuricemia
among community-based screening participants. Contrib Nephrol.
192:41–47. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Waldman M, Beck LH Jr, Braun M, Wilkins K,
Balow JE and Austin HA III: Membranous nephropathy: Pilot study of
a novel regimen combining cyclosporine and rituximab. Kidney Int
Rep. 1:73–84. 2016.PubMed/NCBI View Article : Google Scholar
|
